Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

The board (the "**Board**") of directors (the "**Directors**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**") is pleased to announce the unaudited interim results of the Company and its subsidiaries (collectively, the "**Group**") for the six months ended June 30, 2025 (the "**Reporting Period**"), together with the comparative figures for the corresponding period in 2024.

In this announcement, "**we**", "**us**" and "**our**" refer to the Company and the Group, depending on the context.

FINANCIAL HIGHLIGHTS

For the six months ended June 30, 2025, the Group recorded the following unaudited results:

- Revenue was approximately RMB7,434 million, representing an increase of approximately 14.3% compared with the corresponding period of the previous year;
- Revenue of innovative drugs and collaborative products amounted to approximately RMB6,145 million, representing an increase of approximately 22.1% compared with the corresponding period of the previous year, and its proportion of total revenue increased to approximately 82.7%;
- R&D expenditure was approximately RMB1,441 million, representing an increase of approximately 20.4% compared with the corresponding period of the previous year, and accounted for approximately 19.4% of the revenue;
- Profit was approximately RMB3,135 million, representing an increase of approximately 15.0% compared with the corresponding period of the previous year;
- Basic earnings per share was approximately RMB0.53, representing an increase of approximately 14.8% compared with the corresponding period of the previous year.

The increase in revenue, profit and basic earnings per share during the Reporting Period was primarily due to the increase in revenue of innovative drugs and collaborative products.

The Board has declared the payment of an interim dividend of HK$23.16 cents per share for the six months ended June 30, 2025.

CORPORATE OVERVIEW

The Company is a leading innovation-driven pharmaceutical enterprise in the People's Republic of China ("**China**" or "**PRC**"). With the mission of "continuous innovation for better life", the Company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system ("**CNS**"), metabolism and autoimmunity. The Company has launched seven innovative drugs that generate product sales in the PRC, forming a rich product pipeline. For the six months ended June 30, 2025, the revenue of innovative drugs and collaborative products amounted to approximately RMB6,145 million and accounted for approximately 82.7% of the revenue, becoming a core driver for sustainable growth of the Group's performance.

The major achievements during the Reporting Period were as follows:

In January 2025, GlaxoSmithKline Intellectual Property (No. 4) Limited ("**GSK**"), the Group's collaborator, received the U.S. Food and Drug Administration (the "**FDA**") Breakthrough Therapy Designation for GSK5764227 (Company code HS-20093), the B7-H3-targeted antibody-drug conjugate ("**ADC**") being evaluated for the treatment of adult patients with relapsed or refractory osteosarcoma (bone cancer) who have progressed on at least two prior lines of therapy.

In February 2025, based on the positive results from the global pivotal phase III MITIGATE trial on XINYUE (昕越®) (Inebilizumab Injection), the new indication of the treatment of immunoglobulin G4-related disease ("**IgG4-RD**") of the product has been included in the Priority Review and Approval Procedure by the National Medical Products Administration of China (中國國家藥品監督管理局) (the "**NMPA**"). In March 2025, Biologics License Application ("**BLA**") of this indication was accepted by the NMPA.

In February 2025, the Category 1 small molecule Bruton's tyrosine kinase inhibitor ("**BTKi**") HS-10561 capsules, which is jointly developed by the Group and Guangzhou Lupeng Pharmaceutical Co., Ltd.* (廣州麓鵬製藥有限公司) ("**Lupeng Pharma**"), obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for chronic spontaneous urticaria.

In February 2025, the NMPA listed the Group's self-developed B7-H3-targeted ADC HS-20093 for injection as a Breakthrough-Therapy-Designated ("**BTD**") Drug, with the proposed indication for the treatment of patients with osteosarcoma who have progressed on at least two prior lines of therapy.

In March 2025, Ameile (阿美樂®) (Aumolertinib Mesilate Tablets), an innovative drug of the Group, was granted drug registration approval by the NMPA, approving the addition of an indication: for the treatment of patients with locally advanced, unresectable non-small cell lung cancer ("**NSCLC**") whose disease has not progressed following definitive platinum-based chemoradiotherapy whose tumors have epidermal growth factor receptor ("**EGFR**") exon 19 deletions or exon 21 (L858R) substitute mutations. This is the third indication of Ameile which has been approved. In May 2025, Ameile was granted another drug registration approval by the NMPA, approving the addition of an indication: for the treatment of adult patients with stage II to IIIB NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutations, and who have undergone tumor resection with or without prior adjuvant chemotherapy as determined by their physician. This is the fourth indication of Ameile which has been approved.

In April 2025, HS-20122 for injection, which is an ADC of the Group, obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma, or colorectal cancer.

In April 2025, the innovative drug HS-20108 for injection, self-developed by the Group, obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for advanced solid tumors such as small cell lung cancer and neuroendocrine tumors.

In April 2025, HS-10529 tablets, a small molecule innovative drug targeting KRAS G12D self-developed by the Group, obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for advanced solid tumors (pancreatic cancer, colorectal cancer, NSCLC, etc.) with KRAS G12D mutations.

In April 2025, the NMPA listed HS-20093 for injection, the Group's self-developed B7-H3-targeted ADC, as a BTD Drug again, with the proposed indication for locally advanced or metastatic non-squamous NSCLC without driver mutations, progressed or recurred following platinum-based chemotherapy.

In April 2025, Hengmeida (恒美達®) (Ibrexafungerp Tablets) was granted drug registration approval by the NMPA for the treatment of vulvovaginal candidiasis (VVC) in adult and post menarche adolescent women.

In May 2025, the NMPA listed HS-20089 for injection, the Group's self-developed B7-H4-targeted ADC, as a BTD Drug, with the proposed indication for platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer patients.

In May 2025, HS-20118 tablets, a Category 1 innovative drug self-developed by the Group, obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for moderate to severe plaque psoriasis.

In May 2025, HS-10542 capsules, a Category 1 innovative drug self-developed by the Group, obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for paroxysmal nocturnal hemoglobinuria (PNH) and immunoglobulin A nephropathy (IgAN).

In May 2025, HS-10510 tablets, a Category 1 innovative drug self-developed by the Group, obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for primary hypercholesterolemia and mixed dyslipidemia.

In May 2025, the third BLA of XINYUE was accepted by the NMPA, which is for the treatment of generalized myasthenia gravis (gMG) in adult patients.

In June 2025, the Group entered into a license agreement with Regeneron Pharmaceuticals, Inc. ("**Regeneron**"), pursuant to which the Group has granted Regeneron an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong and Macau) to develop, manufacture and commercialize HS-20094.

In June 2025, Aumolertinib Mesilate Tablets (trade name in the United Kingdom: Aumseqa®), the Group's innovative drug, was approved by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom ("**MHRA**") for marketing. Aumseqa® as monotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

The Company continued to make improvements in environmental, social and governance ("**ESG**") aspects. During the Reporting Period, the Company maintained an MSCI ESG rating of AA, was again selected for inclusion in the *Sustainability Yearbook (Global Edition) 2025* and the *Sustainability Yearbook (China Edition) 2025* published by S&P Global ("**S&P**"), and ranked among the top 1% in the Chinese pharmaceutical industry. These developments not only indicate the Company's past achievements in the ESG field, but also represent our long-term commitment and strategic plan for sustainable development.

There is no material event affecting the Company during the period from June 30, 2025 to the date of this announcement.

The website of the Group: **www.hspharm.com/**

MANAGEMENT DISCUSSION AND ANALYSIS

Industry Review

2025 marks the culmination of China's 14th Five-Year Plan period. During this period, China has firmly maintained its position as the world's second-largest pharmaceutical market, the number of clinical studies has jumped to the top in the world, innovative talents have emerged, and professional long-term strategic investments guided by policies have continued to expand. Innovative drugs, as a new form of productivity, have rapidly developed. High-value innovative drugs continue to be approved for marketing, quickly benefiting patients and addressing unmet clinical needs. A large number of domestic innovative drugs have successfully gone abroad, especially in cutting-edge fields such as ADC, bispecific antibodies, cell therapies, AI-assisted drug discovery, etc. China's original targets and drugs are particularly outstanding. A solid market foundation, development measures supported by the entire chain, and a solid talent pool provide guarantees for promoting the high-quality development of innovative drugs in China and participating in global competition.

Business Highlights

For the six months ended June 30, 2025, the Group recorded revenue of approximately RMB7,434 million, representing an increase of approximately 14.3% compared with the corresponding period of the previous year; profit of approximately RMB3,135 million, representing an increase of approximately 15.0% compared with the corresponding period of the previous year; basic earnings per share of approximately RMB0.53, representing an increase of approximately 14.8% compared with the corresponding period of the previous year; revenue of innovative drugs and collaborative products amounted to approximately RMB6,145 million, and its proportion of total revenue increased to approximately 82.7%.

We generate our revenue primarily from sales of pharmaceutical products. Our main products are concentrated in the main therapeutic areas on which the Group strategically targets, including oncology, anti-infectives, CNS, metabolic and other diseases. The increase in revenue, profit and basic earnings per share during the Reporting Period was primarily due to the increase in the revenue of innovative drugs and collaborative products.

For the six months ended June 30, 2025, the revenue and product portfolio of our therapeutic areas are as follows:

Therapeutic Area	Product Portfolio
Oncology (revenue amounted to approximately RMB4,531 million, accounting for approximately 60.9% of the total revenue)	Innovative drug Ameile (Aumolertinib Mesilate Tablets), innovative drug Hansoh Xinfu (Flumatinib Mesylate Tablets), Pulaile (Pemetrexed Disodium for Injection), Pulaitan (Enzalutamide Soft Capsules) and Xinwei (Imatinib Mesylate Tablets), etc.
Anti-infectives (revenue amounted to approximately RMB735 million, accounting for approximately 9.9% of the total revenue)	Innovative drug Hengmu (Tenofovir Amibufenamide Tablets), innovative drug Mailingda (Morinidazole Sodium Chloride for Injection) and Hengsen (Micafungin Sodium for Injection), etc.
CNS (revenue amounted to approximately RMB768 million, accounting for approximately 10.4% of the total revenue)	Innovative drug XINYUE (Inebilizumab Injection), Ameining (Agomelatine Tablets), Ailanning (Paliperidone Extended-Release Tablets) and Oulanning (Olanzapine Tablets/Orally Disintegrating Tablets/Oral Soluble Film), etc.
Metabolic and other diseases (revenue amounted to approximately RMB1,400 million, accounting for approximately 18.8% of the total revenue)	Innovative drug Fulaimei (PEG-Loxenatide for Injection), innovative drug Saint Luolai (Pegmolesatide Injection), Fulaidi (Repaglinide Tablets) and Punuoan (Ambrisentan Tablets), etc.

Innovative drug products

Ameile (阿美樂®)

Ameile (Aumolertinib Mesilate Tablets) is the first original third-generation EGFR-tyrosine kinase inhibitor ("**TKI**") innovative drug in China self-developed by the Group. It has been approved for four indications in China. In March 2020, it was approved for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation positive, who have progressed on or after EGFR-TKI therapy; in December 2021, it was approved as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive. The above two indications were successfully renewed in November 2024 for inclusion in the 2024 National Reimbursement Drug List ("**NRDL**"). Ameile is continuously expanding its indications and increasing its evidence from evidence-based medicine. During the Reporting Period, a total of two NDAs for new indications were approved by the NMPA, namely:

In March 2025, Ameile was approved for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following definitive platinum-based chemoradiotherapy whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutations.

In May 2025, it was approved for the treatment of adult patients with stage II to IIIB NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutations, and who have undergone tumor resection with or without prior adjuvant chemotherapy as determined by their physician.

In June 2025, Ameile (trade name in the United Kingdom: Aumseqa®) was approved by the MHRA for marketing. Aumseqa® as monotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

Ameile has been recommended as Class I or Preferred by eight national diagnosis and treatment guidelines, including the *Chinese Society of Clinical Oncology (CSCO) Guidelines for the treatment of Non-small Cell Lung Cancer (2025 edition)** (《中國臨床腫瘤學會非小細胞肺癌診療指南(2025版)》). During the Reporting Period, nine academic findings of Ameile were presented at authoritative conferences, including the annual meetings of American Association for Cancer Research ("**AACR**"), European Lung Cancer Congress (ELCC), American Society of Clinical Oncology (ASCO), of which data for two phase III clinical trials were selected for verbal presentations at the AACR 2025 Annual Meeting in April 2025, namely:

Phase III clinical trial data for Ameile for adjuvant treatment of NSCLC post-surgery. The data shows that for patients with stage II to IIIB NSCLC whose tumors have EGFR mutations and who have undergone complete tumor resection, following Ameile adjuvant therapy as appropriate, their disease-free survival (DFS) has been significantly improved with HR of 0.17 and a high 2-year DFS of 90.2%, with safety profile manageable on the whole.

Phase III clinical trial data for Ameile in combination with chemotherapy as first line therapy for advanced NSCLC. The data shows that for patients with locally advanced or metastatic NSCLC whose tumors have EGFR-sensitive mutations, progression-free survival (PFS) of the patients with Ameile in combination with chemotherapy as first line therapy has been significantly extended with HR of 0.47 as compared to monotherapy, suggesting that Ameile in combination with chemotherapy can reduce 53% of risks of disease progression or death, as compared to monotherapy. Median progression-free survival (mPFS) has been extended to 28.9 months and objective response rate (ORR) reached a height of 93.2%. No new safety risk has been identified.

Hansoh Xinfu (豪森昕福®)

Hansoh Xinfu (Flumatinib Mesylate Tablets) is the first original novel second-generation TKI for chronic myelogenous leukemia in China, which was approved for marketing in 2019. It was included in the NRDL through negotiations in 2020 and was successfully renewed in November 2024 for inclusion in the 2024 NRDL. Hansoh Xinfu is used in the treatment of chronic myelogenous leukemia. Based on results of existing clinical trials, Hansoh Xinfu achieved faster and deeper molecular remission (e.g. MMR, MR4.5). It also has favorable safety profile, with no specific adverse reactions (such as pleural effusion or cardiotoxicity) relating to the use of other second-generation BCR-ABL TKI treatments being found, and has been adopted for long-term application by an increasing number of patients. Hansoh Xinfu has been recommended as the first-line treatment for chronic myelogenous leukemia in the *Guidelines for Diagnosis and Treatment of Chronic Myelogenous Leukemia** (《慢性髓性白血病診斷與治療指南》) released by the National Health Commission of the PRC (中國國家衛生健康委員會) ("**NHC**") and the *Guidelines for Diagnosis and Treatment of Malignant Hematologic Diseases** (《惡性血液病診療指南》).

During the Reporting Period, multiple clinical studies of Hansoh Xinfu were presented at the 30th session of the Annual Meeting of the European Hematology Association (EHA).

XINYUE (昕越®)

XINYUE (Inebilizumab Injection) is a targeted CD19 B-cell depleting antibody and the world's first humanized CD19 monoclonal antibody approved for the treatment of adult patients with anti-aquaporin-4 ("**AQP4**") antibody-positive neuromyelitis optica spectrum disorder ("**NMOSD**"). On May 24, 2019, the Group entered into a license agreement with Viela Bio Inc. (which was acquired by Horizon Therapeutics plc in 2021, and the latter was acquired by Amgen INC ("**Amgen**") in 2023) to obtain an exclusive license to develop and commercialize the product in Chinese Mainland, Hong Kong and Macau. On March 14, 2022, the product was approved by the NMPA for marketing in China and is indicated for the treatment of adult NMOSD patients who are AQP4 antibody positive. In January 2023, the product was included in the NRDL for the first time, and was successfully renewed in November 2024 for inclusion in the 2024 NRDL.

In February 2025, based on positive results from the global pivotal phase III MITIGATE trial on XINYUE, the new indication of the product for the treatment of IgG4-RD was included in the Priority Review and Approval Procedure by the NMPA.

In March 2025, BLA of this indication was accepted by the NMPA. It is also the second BLA of XINYUE.

In April 2025, Amgen, a collaborator of the Company, announced that inebilizumab for the treatment of IgG4-RD in adult patients had been approved by the FDA, making it the first drug approved by the FDA for the treatment of IgG4-related diseases.

In May 2025, the third BLA for the product was accepted by the NMPA for the treatment of adult patients with generalized myasthenia gravis (gMG).

Fulaimei (孚來美®)

Fulaimei (PEG-Loxenatide for Injection) is the first innovative drug launched leveraging on the Group's proprietary PEGylation technology. It is the first original glucagon-like peptide-1 ("**GLP-1**") receptor agonist ("**GLP-1RA**") weekly formulation in China and the world's first PEG GLP-1RA weekly formulation, which was approved for marketing in May 2019 for the treatment of type 2 diabetes mellitus. Fulaimei provides a new treatment option that is safe, effective and convenient for type 2 diabetic patients in China, with clear efficacy in lowering blood glucose, combined with weight loss, lowering of cholesterol and blood pressure, renal and cardiovascular benefits, as well as low incidence of gastrointestinal reactions and hypoglycemic adverse events, while requiring only one subcutaneous injection per week. Fulaimei was first included in the NRDL in 2020 through negotiation, and was successfully renewed in November 2024 for inclusion in the 2024 NRDL.

During the Reporting Period, multiple research findings related to Fulaimei were published in internationally renowned journals, including the results of a large-scale multicenter bidirectional cohort real-world study on cardiovascular safety published in *MedComm* (IF:10.7), the results of a real-world study on Fulaimei in combination with insulin therapy published in *Diabetes Therapy*, as well as multiple action mechanism studies on Fulaimei promoting wound healing, improving insulin resistance and lipid metabolism disorders. These results provide new strategies for the clinical treatment of patients with type 2 diabetes and related complications, and support broader clinical application prospects of Fulaimei.

Fulaimei has been included in the *Guidelines for the Prevention and Treatment of Diabetes Mellitus in China (2024 edition)** (《中國糖尿病防治指南(2024版)》) released by the Chinese Diabetes Society (CDS). It was also included in the *Chinese Expert Consensus on the Comprehensive Management of Patients with Cardiovascular-Kidney-Metabolic Syndrome** (《心血管－腎臟－代謝綜合徵患者的綜合管理中國專家共識》) in March 2025, and was recommended by the *Expert Consensus on Combination Treatment with a Glucagon-like Peptide-1 Receptor Agonist and Insulin for Treatment of Type 2 Diabetes (2025)** (《胰高糖素樣肽1受體激動劑聯合胰島素治療2型糖尿病專家共識(2025版)》) in April 2025.

Hengmu (恒沐®)

Hengmu (Tenofovir Amibufenamide Tablets) is a novel nucleotide reverse transcriptase inhibitor (NRTI) self-developed by the Group, which is the first wholly developed oral dose medicine indicated for the treatment of hepatitis B virus infection in China. Hengmu was approved for marketing by the NMPA in June 2021 for the treatment of adult patients with chronic hepatitis B. Hengmu was included in the NRDL in the same year, and successfully renewed in December 2023, and currently within the term of the agreement.

The 48-week, 96-week and 144-week follow-up data of the phase III registration clinical study and the research data of the phase IV study with a follow-up period of up to 5 years of Hengmu have been published in several academic journals and international conferences. The results of the studies strongly confirmed the efficacy and safety of Hengmu in the long-term treatment of patients with chronic hepatitis B. Specifically, in terms of bone and renal safety, Hengmu has more advantages over tenofovir disoproxil fumarate (TDF).

As of the date of this announcement, findings on multiple clinical studies of Hengmu were presented at top international academic conferences in the field of hepatology, including the American Association for the Study of Liver Diseases (AASLD) Annual Meeting, the European Association for the Study of the Liver (EASL) Annual Meeting and the Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting, and were published in domestic and international journals such as *Alimentary Pharmacology & Therapeutics*, *Frontiers In Pharmacology*, *World Journal of Gastroenterology*, *Journal of Clinical and Translational Hepatology* and *Chinese Journal of Hepatology*.

Hengmu was included in the *Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Version)** (《慢性乙型肝炎防治指南(2022年版)》) in February 2023, and was also included in the *Chinese Society of Clinical Oncology: Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma, 2022** (《中國臨床腫瘤學會肝癌診療指南(2022年版)》) as Class I recommendation. In April 2024, Hengmu received a Class A recommendation in the *Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition)** (《原發性肝癌診療指南(2024年版)》) issued by the NHC. In October 2024, Hengmu received a Class A2 recommendation in the *Guidelines for the Diagnosis and Treatment of Liver Failure (2024 Edition)** (《肝衰竭診治指南(2024年版)》) issued by the Chinese Society of Infectious Diseases under the Chinese Medical Association.

Saint Luolai (聖羅萊®)

Saint Luolai (Pegmolesatide Injection), is the "only class 1 small molecule peptide chemical drug approved for marketing worldwide in the field of renal anaemia treatment" self-developed by the Group. In June 2023, Saint Luolai was approved for two indications to treat anemia in chronic kidney disease (CKD) adult patients who have not received erythropoiesis-stimulating agent (ESA) and are not on dialysis, as well as those who are receiving short-acting erythropoietin treatment and on dialysis. In the same year, Saint Luolai was included in the NRDL for the first time, and currently within the term of the agreement.

Saint Luolai has high affinity and selectivity to erythropoietin ("**EPO**") receptor. It effectively promotes erythropoiesis and assists in reducing potential safety risks. The data of the phase III pivotal registrational clinical trial of Saint Luolai (published in *eClinical Medicine*, a subset of *The Lancet* in 2023) demonstrated that, subcutaneous injection of Saint Luolai once a month is as effective and safe as fast-acting recombinant human erythropoietin (rHuEPO) conventionally administered 1 to 3 times a week in treating anemia in Chinese dialysis patients. It even shows a trend of superiority and a lower incidence of adverse cardiovascular events. Latest studies found that the mechanism bringing about Pegmolesatide's prolonged anti-anemia effects not only results from higher pharmacokinetic half-life due to PEGylation, but is also related to mechanisms such as Pegmolesatide's enhanced EPO receptor binding stability.

As of the date of this announcement, multiple research findings of Saint Luolai have been published in top-tier journals or medical conferences, including *Journal of Translational Medicine*, *Kidney International Reports*, *Kidney Medicine*, as well as the American Society of Nephrology (ASN) Annual Meeting, the International Society of Nephrology (ISN) and the World Congress of Nephrology (WCN).

In February 2024, Saint Luolai was included for the first time in the *Chinese Expert Consensus on Long-acting Erythropoiesis-stimulating Agents in the Treatment of Renal Anemia (2024)** (《長效紅細胞生成刺激劑治療腎性貧血中國專家共識(2024年版)》). In January 2025, Saint Luolai was included in the *Chinese Expert Consensus on Guiding Self-management of Patients with Renal Anemia (2024)** (《指導腎性貧血患者自我管理的中國專家共識(2024版)》). In July 2025, Saint Luolai was recommended by *Clinical Practice Guideline for Delaying the Progression of Chronic Kidney Disease (2025)** (《延緩慢性腎臟病進展臨床管理指南(2025年版)》) for therapy and management of renal anemia.

R&D and Innovation

Innovation focus is the core driving force of our Company's development. The Group has continuously increased its investments in R&D over the years, built complete R&D platforms, established a number of proprietary technologies, developed and commercialized a number of innovative drug products, as well as prepared a series of innovative drugs which are currently at different stages of R&D. Our professional R&D team consists of over 1,900 research fellows at four R&D centres located in Maryland, United States and Shanghai, Changzhou and Lianyungang, China. We have several national-level R&D designations, including the National Technology Center* (國家級技術中心), Post-doctoral Research Station* (博士後科研工作站) and Key National Laboratory* (國家重點實驗室).

During the six months ended June 30, 2025, we submitted 24 formal patent applications in China and 11 patents were granted; we submitted 58 formal overseas patent applications and 30 patents were granted.

R&D pipeline update

During the six months ended June 30, 2025, the Group had more than 70 clinical trials of innovative drugs being investigated, covering more than 40 innovative drug candidates.

During the Reporting Period, we had eight new innovative drug candidates entering clinical stage, including the small molecule BTK inhibitor HS-10561 (for chronic spontaneous urticaria); an ADC HS-20108 (for advanced solid tumors such as small cell lung cancer and neuroendocrine tumors); HS-20122, an ADC targeting EGFR/c-Met (for advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma, or colorectal cancer); HS-10542 (for paroxysmal nocturnal hemoglobinuria and immunoglobulin A nephropathy); HS-10510 (for primary hypercholesterolemia and mixed dyslipidemia); HS-10529, a small molecule KRAS G12D inhibitor (for advanced solid tumors with KRAS G12D mutations such as pancreatic cancer, colorectal cancer, NSCLC); and HS-20118 (for moderate to severe plaque psoriasis), etc.

During the Reporting Period, new phase III pivotal registration clinical trials were added, including: HS-20093, a self-developed B7-H3-targeted ADC (for bone and soft tissue sarcoma); HS-20089, a self-developed B7-H4-targeted ADC (for ovarian cancer); and HS-20137, a monoclonal antibody drug targeting IL-23p19 developed in collaboration with Qyuns Therapeutics Co., Ltd. ("**Qyuns**") (for moderate to severe plaque psoriasis).

R&D progress of key products

HS-20093

HS-20093, a B7-H3-targeted ADC self-developed by the Group, is composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to topoisomerase inhibitor (TOPOi) payload.

During the Reporting Period, HS-20093 has entered phase III clinical research for the treatment of bone and soft tissue sarcoma indication in China. Currently, HS-20093 has entered phase III clinical research for the treatment of small cell lung cancer indication in China, and is also undergoing multiple proofs of concept (PoC) clinical studies for the treatment of head and neck cancer, castrate-resistant prostate cancer, esophageal squamous cell carcinoma and other solid tumors.

In February 2025, the NMPA listed HS-20093 as a BTD Drug, with the proposed indication for the treatment of patients with osteosarcoma who have progressed on at least two prior lines of therapy.

In April 2025, HS-20093 was approved by the NMPA as a BTD Drug again, with the proposed indication for locally advanced or metastatic non-squamous NSCLC without driver mutations, progressed or recurred following platinum-based chemotherapy.

Prior to this, HS-20093 had been approved by the NMPA for inclusion as a BTD Drug, with the proposed indication for extensive-stage small-cell lung cancer that has developed after standard first-line treatment (platinum doublet chemotherapy combined with immunotherapy).

HS-20089

HS-20089 is a B7-H4-targeted ADC self-developed by the Group.

During the Reporting Period, HS-20089 has entered phase III clinical research for the treatment of the ovarian cancer indication in China and currently is also undergoing PoC clinical studies for the treatment of endometrial cancer and other solid tumors.

In May 2025, HS-20089 was approved by the NMPA as a Breakthrough-Therapy-Designated Drug, with the proposed indication for platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

HS-20094

HS-20094 is a dual glucose-dependent insulinotropic polypeptide ("**GIP**") and GLP-1 receptor agonist self-developed by the Group. By selectively activating both the GIP and GLP-1 receptors, it promotes insulin secretion, delays gastric emptying, inhibits appetite and reduces food intake, thereby producing biological effects such as glucose control, weight loss, and metabolic improvement. Its administration method is once a week via subcutaneous injection. The relevant clinical studies have administered the drug to over a thousand subjects. Currently, we are actively advancing phase III clinical studies of HS-20094 for obesity or overweight.

HS-10374

HS-10374 is a selective allosteric inhibitor of tyrosine kinase 2 ("**TYK2**") self-developed by the Group. In phase II clinical trial in patients with moderate-to-severe plaque psoriasis, HS-10374 demonstrated significant efficacy, with overall safety similar to other TYK2 inhibitors and a lower risk of skin-related toxicity. Currently, we are actively advancing phase III clinical studies of HS-10374 in adult patients with moderate-to-severe plaque psoriasis.

Business Development

As an important part of our daily business, the Group pays close attention to the cutting-edge developments in the global pharmaceutical industry and proactively seizes opportunities for out-licensing and collaboration in BD. On December 18, 2024, the Group entered into a license agreement with a wholly-owned subsidiary of Merck Sharp & Dohme LLC ("**MSD**"), pursuant to which, the Group received an upfront payment of US$112 million of BD license fee from collaborator MSD during the Reporting Period, which was included in collaboration revenue. In addition, the Group entered into an out-licensing for HS-20094 with Regeneron on June 2, 2025. See below for details.

Collaboration with Regeneron

On June 2, 2025, Shanghai Hansoh Biomedical Co., Ltd.* (上海翰森生物醫藥科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Co., Ltd.* (江蘇豪森藥業集團有限公司), wholly-owned subsidiaries of the Company, entered into a license agreement with Regeneron. Pursuant to the license agreement, the Group granted an exclusive worldwide license (excluding Chinese Mainland, Hong Kong, and Macau) to Regeneron to develop, manufacture, and commercialize HS-20094. The Group received an upfront payment of US$80 million in July 2025, and will be eligible to receive up to US$1.93 billion in milestone payments associated with the development, regulatory approval and commercialization of the product, as well as double-digit royalties on potential future product sales.

Clinical Progress of In-licensing and Collaboration Programs

During the Reporting Period, the Group incurred a total of approximately RMB191 million of research and development expenses due to the in-licensed or collaborative projects that had been introduced in the past, which were mainly used to advance the clinical trials of a number of in-licensed projects.

Progress of HS-20122

In March 2024, the Group entered into a licensing agreement with Biotheus Inc. ("**Biotheus**") and obtained an exclusive license from Biotheus to use bispecific antibodies targeting EGFR/c-Met, including HS-20117, for the development, production and commercialization of antibody conjugate products globally, with the right to further sub-license.

HS-20122 is a bispecific ADC developed based on HS-20117 that targets EGFR/c-Met. In April 2025, HS-20122 obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma, or colorectal cancer.

Progress on HS-20137

In April 2024, the Group entered into a licensing agreement with Qyuns and obtained an exclusive license from Qyuns to develop and commercialize HS-20137 monoclonal antibody in China (including Hong Kong, Macau and Taiwan) (collaborator code QX004N). HS-20137 is a monoclonal antibody that targets IL-23p19, currently under development for indications such as psoriasis.

In March 2025, the findings of phase II clinical trial of HS-20137 for plaque psoriasis in adults were presented at the American Academy of Dermatology (AAD) Annual Meeting. The trial results show that during the 28-week treatment period, HS-20137 shows strong efficacy and favorable safety profile in patients with moderate to severe plaque psoriasis. The results were consistent with the phase I study results published in *JAMA Dermatology*.

During the Reporting Period, the indication of HS-20137 for the treatment of psoriasis has entered into phase III clinical study in China.

Progress on HS-10561

In August 2024, the Group entered into a licensing agreement with Lupeng Pharma and obtained an exclusive license from Lupeng Pharma to develop and commercialize HS-10561 (collaborator code LP-168) in China (including Hong Kong, Macau and Taiwan). The Group is responsible for the research and development, regulatory approval, manufacturing and commercialization of this product in all non-oncology indications in China.

HS-10561 is a small molecule BTKi. In February 2025, HS-10561 capsules received a drug clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for chronic spontaneous urticaria.

Environmental, Social and Governance (ESG)

Adhering to our core values of "responsibility, integrity, hard work and innovation", the Group has in the long term been committed to improving the accessibility of innovative drugs in the areas of unfulfilled clinical needs. During the Reporting Period, we have achieved continuous improvement in various aspects such as innovative achievements, strengthening of governance, green development, talent cultivation and inclusive healthcare, laying a solid foundation for the Company's long-term development. We are continuously improving the disclosures of our governance, strategy, risk management, metrics and targets on key ESG issues in response to stakeholders' concerns and striving towards a higher level of ESG management to lower operating risks.

In the first half of 2025, the Board continued to perform its supervisory duties and, through the ESG Committee, regularly reviewed risk prevention strategies and systems, ESG strategies and emerging risks, as well as key performance indicators that reflect the comprehensive improvement of ESG results, and responded to identified hidden hazards or potential risks with forward-looking actions.

During the Reporting Period, we engaged a third party to provide independent assurance on our 2024 ESG report, and continued to conduct systematic inspections and third-party verification of Scope 1, Scope 2 and Scope 3 greenhouse gases, to ensure accuracy, completeness and reliability of information and data for ESG disclosure.

During the Reporting Period, the Group maintained an MSCI ESG rating of AA and achieved industry leading standards in five key issues including corporate behavior, as well as toxic emissions and waste. At the same time, the Group was again selected for inclusion in the *Sustainability Yearbook (Global Edition) 2025* and the *Sustainability Yearbook (China Edition) 2025* published by S&P, and ranked among the top 1% in the Chinese pharmaceutical industry.

We actively respond to the Sustainable Development Goals of the United Nations, closely linking ESG management to the Company's long-term strategies, and better cope with global challenges by focusing on ESG issues. We are committed to sharing good practices with our industry partners and supply chains, striving to enable more patients to benefit from green innovations. This is not only conducive to natural environment protection and social welfare, but also beneficial to creating a more stable and sustainable business environment, realizing coordinated economic, social and environmental development. We will continue to adhere to the philosophy of being "patient-centered and innovation-driven" and actively contribute our efforts as a responsible corporate citizen.

Liquidity and Financial Resources

Currently, the Group follows a set of funding and treasury policies to manage its capital resources and mitigate potential risks. The Board considers various funding sources depending on the Group's funding needs to ensure that the financial resources have been used in the most cost-effective and efficient way. We also closely monitor uses of cash resources and strive to maintain healthy liquidity for the needs of our business operations.

For the six months ended June 30, 2025, the Group's operating activities generated a net cash inflow of RMB3,605 million. The capital expenditure during the Reporting Period was RMB245 million, mainly relating to the construction of workshops, as well as, among other things, the purchase of equipment, motor vehicles and software required for production, R&D and administrative activities, etc. The cash flow of financing activities for the Reporting Period mainly consisted of proceeds from employees for subscription of shares under the share award scheme of RMB31 million.

The Group's financial position remains sound. As at June 30, 2025, we had cash and bank balances of RMB27,104 million (as at December 31, 2024: RMB22,622 million), current financial assets at fair value through profit or loss of RMB18 million (as at December 31, 2024: RMB17 million). As at June 30, 2025, our current financial assets at fair value through profit or loss primarily comprised financial products issued by commercial banks. As each of the financial products was subscribed with different banks under different terms and are of different nature and none of the financial products exceeds 5% of the applicable percentage ratios on a standalone basis, the Group's purchase of financial products during the six months ended June 30, 2025 does not constitute notifiable transactions of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). As at June 30, 2025, the Group's gearing ratio (calculated as total liabilities divided by total assets) was approximately 11.3% (as at December 31, 2024: 9.4%). After reviewing the Group's profitability, working capital and capital expenditure requirements, the Board is of the view that the Group has no significant liquidity risk and has sufficient working capital.

Most of the Group's assets and liabilities are denominated in Renminbi and United States Dollars. The Group manages its foreign exchange risk by closely monitoring its net foreign exchange exposure to reduce the impact of foreign exchange fluctuations.

Pledge of Group Assets

As at June 30, 2025, none of the Group's assets was subject to any encumbrance, mortgage, lien, charge or pledge.

Contingent Liabilities

As at June 30, 2025, the Group had no material contingent liabilities.

Significant Investments Held

During the six months ended June 30, 2025, the Group did not have any significant investments.

Future Plans for Material Investments and Capital Assets

As at June 30, 2025, the Group did not have any plans for material investments and capital assets.

Material Acquisitions and Disposals

During the six months ended June 30, 2025, the Group did not have any material acquisitions or disposals of subsidiaries, associates or joint ventures.

Employees and Emoluments Policy

As at June 30, 2025, the Group had a total of 9,313 full-time employees, whose remuneration was determined based on their performance and experience as well as the prevailing market salary levels.

The staff costs, including remuneration of the executive Directors, social welfare and other benefits, were approximately RMB1,575 million for the six months ended June 30, 2025. We also provided regular training to employees designed to strengthen staff commitment to us and improve staff knowledge in a number of important areas of our services, such as knowledge about the Company and our products as well as sales, laws and regulations applicable to our operation, requirements under applicable GMP or other certifications, quality control, production safety and corporate culture.

The Company has conditionally approved and adopted the restricted share unit scheme ("**RSU Scheme**") on May 27, 2019 to recognize contributions by selected participants and give incentives thereto in order to retain them for the continual operation and development of the Group and to attract suitable personnel for further development of the Group. Participants may include employees of the Group (including director, chief executive officer, vice president, financial controller, company secretary, members of senior management or key technical personnel) as well as any other person selected by the Board at its sole discretion from time to time (subject to compliance with the applicable Listing Rules).

On April 22, 2025, pursuant to the terms of the RSU Scheme, the Company allotted and issued 11,500,000 new ordinary shares (aggregate nominal value: HK$115) to Computershare Hong Kong Trustees Limited (the "**RSU Trustee**"), holding such shares for the benefit of the participants of the RSU Scheme, with the issue price per share of HK$2.9595 as measured by the Company, which was arrived at after taking into consideration the number of shares currently held by the RSU Trustee and the purchase prices of the RSUs at the time of measurement, and the closing price per share of the Company on the business day immediately preceding the issuance is HK$22.10. During the Reporting Period, the RSU Trustee was not instructed by the Company to purchase any shares from the open market. As at June 30, 2025, a balance of 1,194,647 shares of the Company was held by the RSU Trustee for settlement of the restricted share units ("**RSUs**") under the RSU Scheme. For details of the RSU Scheme, please refer to the section headed "Statutory and General Information – D. Post-IPO RSU Scheme" in Appendix IV to the prospectus of the Company dated May 31, 2019.

During the Reporting Period, RSUs representing an aggregate of 8,560,990 shares of the Company had been granted by the Company pursuant to the RSU Scheme. Among the grants during the Reporting Period (details of the grants are set out in the announcement of the Company dated April 28, 2025), all RSUs granted to Dr. Lyu Aifeng (representing 211,910 shares of the Company granted), being an executive Director of the Company, only involve existing shares of the Company held or to be held by the RSU Trustee, and no new shares were or will be allotted or issued by the Company for the vesting of such RSUs. According to the director's service contract with the Company, the RSUs granted to him form part of his remuneration package and are therefore exempted from the reporting, announcement and independent shareholders' approval requirements under Rules 14A.73(6) and 14A.95 of the Listing Rules.

Prospects

In 2025, the Company will continue to adapt to the development of the pharmaceutical industry, focusing on innovation and internationalization strategies, deepening our plans in major disease therapeutic fields such as oncology, CNS, metabolism and autoimmunity accelerating the development of core product pipelines, strengthening external cooperation and going global, while balancing profitability and innovation investment to ensure sustainable development.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

FOR THE SIX MONTHS ENDED 30 JUNE 2025

	Notes	For the six months ended 30 June	
		2025	2024
		(unaudited)	(unaudited)
		RMB'000	*RMB'000*
REVENUE	*4*	**7,433,559**	6,505,501
Cost of sales		**(660,786)**	(579,218)
Gross profit		**6,772,773**	5,926,283
Other income	*4*	**578,413**	480,963
Selling and distribution expenses		**(1,817,936)**	(1,720,670)
Administrative expenses		**(342,770)**	(353,898)
Research and development costs		**(1,440,841)**	(1,196,454)
Other expenses, net	*4*	**(61,487)**	(18,038)
PROFIT BEFORE TAX	*5*	**3,688,152**	3,118,186
Income tax expense	*6*	**(553,223)**	(392,661)
PROFIT FOR THE PERIOD		**3,134,929**	2,725,525
Attributable to:			
Owners of the parent		**3,134,929**	2,725,525
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT FOR THE PERIOD			
Basic (RMB)	*8*	**0.53**	0.46
Diluted (RMB)	*8*	**0.53**	0.46

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 JUNE 2025

	For the six months ended 30 June	
	2025	2024
	(unaudited)	(unaudited)
	RMB'000	*RMB'000*
PROFIT FOR THE PERIOD	**3,134,929**	2,725,525
OTHER COMPREHENSIVE (LOSS)/INCOME		
Other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	**(86,108)**	84,657
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods	**(86,108)**	84,657
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX	**(86,108)**	84,657
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**3,048,821**	2,810,182
Attributable to:		
Owners of the parent	**3,048,821**	2,810,182

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 JUNE 2025

	Notes	**30 June 2025 (Unaudited) *RMB'000***	31 December 2024 (Audited) *RMB'000*
NON-CURRENT ASSETS			
Property, plant and equipment		**2,766,188**	2,804,765
Right-of-use assets		**436,812**	442,405
Intangible assets		**289,408**	245,286
Financial assets at fair value through profit or loss		**732,629**	702,283
Prepayments for purchase of property, plant and equipment		**27,259**	21,315
Total non-current assets		**4,252,296**	4,216,054
CURRENT ASSETS			
Inventories		**653,489**	651,224
Trade and bills receivables	*9*	**2,793,734**	3,169,763
Prepayments, other receivables and other assets		**250,624**	234,537
Financial assets at fair value through profit or loss		**17,551**	17,237
Other financial assets		**–**	747,468
Cash and bank balances	*10*	**27,103,694**	22,621,566
Total current assets		**30,819,092**	27,441,795
CURRENT LIABILITIES			
Trade and bills payables	*11*	**268,654**	217,851
Other payables and accruals	*12*	**2,215,450**	2,354,591
Contract liabilities		**186,211**	19,227
Convertible bonds		**40,976**	40,874
Lease liabilities		**17,130**	16,006
Tax payable		**138,773**	46,669
Dividends payable		**733,801**	–
Total current liabilities		**3,600,995**	2,695,218
NET CURRENT ASSETS		**27,218,097**	24,746,577
TOTAL ASSETS LESS CURRENT LIABILITIES		**31,470,393**	28,962,631

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)
30 JUNE 2025

	Notes	**30 June 2025 (Unaudited) *RMB'000***	31 December 2024 (Audited) *RMB'000*
NON-CURRENT LIABILITIES			
Lease liabilities		**58,750**	61,013
Deferred tax liabilities		**293,788**	200,189
Other non-current liabilities		**21,279**	21,515
Total non-current liabilities		**373,817**	282,717
NET ASSETS		**31,096,576**	28,679,914
EQUITY			
Equity attributable to owners of the parent			
Share capital	*13*	**52**	52
Treasury shares		**(3,284)**	(13,215)
Reserves		**31,099,808**	28,693,077
Total equity		**31,096,576**	28,679,914

1. CORPORATE INFORMATION

The Company is an exempted company incorporated in the Cayman Islands with limited liability under the Companies Law of the Cayman Islands.

2.1 BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2025 has been prepared in accordance with HKAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024.

The interim condensed consolidated financial information is presented in Renminbi ("**RMB**"), and all values are rounded to the nearest thousand ("**RMB'000**") except when otherwise indicated.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of the following amended HKFRS Accounting Standard for the first time for the current period's financial information.

Amendments to HKAS 21	*Lack of Exchangeability*

The nature and impact of the amended HKFRS Accounting Standard are described below:

Amendments to HKAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted with and the functional currencies of group entities for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

Information about geographical areas

Since about 80% of the Group's revenue were generated from the sale of pharmaceutical products in Chinese Mainland and most of the Group's identifiable operating assets and liabilities were located in Chinese Mainland, no geographical segment information in accordance with HKFRS 8 *Operating Segments* is presented.

Information about major customers

Other than that the collaboration revenue from a wholly-owned subsidiary of Merck Sharp & Dohme LLC amounted to approximately 10% of the Group's revenue for the six months ended 30 June 2025, no other revenue from the Group's sales to a single customer amounted to 10% or more of the Group's revenue during the Reporting Period.

4. REVENUE, OTHER INCOME AND OTHER EXPENSES, NET

An analysis of revenue and other income is as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from contracts with customers		
Sales of products – at a point in time	**5,776,795**	5,103,080
Collaboration revenue – at a point in time	**1,656,764**	1,402,421
Total	**7,433,559**	6,505,501
Other income		
Investment income	**17,167**	84,646
Government grants	**48,558**	21,918
Bank interest income	**512,393**	374,011
Others	**295**	388
Total	**578,413**	480,963

An analysis of other expenses, net is as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Other expenses, net		
Gain/(loss) on disposal of items of property, plant and equipment	**908**	(499)
Losses on derecognition of financial assets at amortised cost	**–**	(4,805)
Fair value (loss)/gain of financial assets at fair value through profit or loss	**(35,564)**	55,777
Donations	**–**	(30,438)
Exchange differences, net	**(7,496)**	22,595
Impairment of trade receivables, net	**2,369**	(6,943)
Impairment of inventories, net	**(16,698)**	(6,765)
Impairment of property, plant and equipment	**–**	(27,667)
Interest expense	**(1,633)**	(4,943)
Others	**(3,373)**	(14,350)
Total	**(61,487)**	(18,038)

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

		For the six months ended 30 June	
	Notes	**2025**	2024
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Cost of inventories sold		**467,450**	355,191
Depreciation of property, plant and equipment		**176,454**	198,163
Depreciation of right-of-use assets		**14,255**	11,713
Amortisation of intangible assets		**6,565**	6,891
Impairment of trade receivables, net	*4*	**(2,369)**	6,943
Impairment of inventories, net	*4*	**16,698**	6,765
Impairment of property, plant and equipment	*4*	**–**	27,667
Operating lease expenses		**4,125**	3,531
Auditors' remuneration		**1,630**	1,865
(Gain)/loss on disposal of items of property, plant and equipment	*4*	**(908)**	499
Investment income	*4*	**(17,167)**	(84,646)
Fair value loss/(gain) of financial assets at fair value through profit or loss	*4*	**35,564**	(55,777)
Bank interest income	*4*	**(512,393)**	(374,011)
Exchange differences, net	*4*	**7,496**	(22,595)
Employee benefit expense			
Wages and salaries		**1,026,868**	970,726
Social welfare and other benefits*		**469,594**	442,141
Share-based payments		**78,585**	67,587
Total		**1,575,047**	1,480,454

* There are no forfeited contributions that may be used by the Group as the employer to reduce the existing level of contributions.

6. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Islands, the Group is not subject to any income tax in the Cayman Islands and the British Virgin Islands.

The subsidiaries incorporated in Hong Kong and the subsidiaries registered as Hong Kong tax residents are subject to income tax at the rate of 16.5% (2024: 16.5%) on the estimated assessable profits arising in Hong Kong during the Reporting Period. The first HK$2,000,000 (2024: HK$2,000,000) of assessable profits of each subsidiary are taxed at 8.25% (2024: 8.25%) and the remaining assessable profits are taxed at 16.5% (2024: 16.5%).

The provision for the PRC enterprise income tax is based on the statutory rate of 25% of the assessable profits of certain PRC subsidiaries of the Group as determined in accordance with the Enterprise Income Tax Law of the PRC which was approved and became effective on 1 January 2008, except for certain subsidiaries of the Group in Chinese Mainland which are granted tax concession and are taxed at preferential tax rates.

In 2023, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and Shanghai Hansoh Biomedical Co., Ltd., subsidiaries of the Company, renewed their "High and New Technology Enterprise" ("**HNTE**") qualification and were entitled to a preferential income tax rate of 15% for a period of three years from 2023 to 2025.

In 2024, Changzhou Hansoh Pharmaceutical Co., Ltd. a subsidiary of the Company, renewed its HNTE qualification and was entitled to a preferential income tax rate of 15% for the period from 2024 to 2026.

The income tax expense of the Group for the periods presented is analysed as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current income tax	**459,624**	396,930
Deferred income tax	**93,599**	(4,269)
Total	**553,223**	392,661

7. DIVIDENDS

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
2024 final dividends declared – HK$13.53 cents per ordinary share (2023 final dividends declared – HK$14.22 cents per ordinary share)	**734,910**	768,760

Pursuant to the resolutions of the shareholders of the Company dated 20 June 2025, the Company declared dividends of HK$13.53 cents per ordinary share (13 June 2024: HK$14.22 cents per ordinary share), amounting to a total of approximately RMB734,910,000 (six months ended 30 June 2024: RMB768,760,000).

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of basic earnings per share is based on the profit for the period attributable to ordinary equity holders of the parent of RMB3,134,929,000 (six months ended 30 June 2024: RMB2,725,525,000), and the weighted average number of ordinary shares of 5,937,754,754 (six months ended 30 June 2024: 5,925,786,074) outstanding during the period, which are adjusted to reflect the changes in the number of ordinary shares during the period.

The calculation of the diluted earnings per share amount is based on the profit for the period attributable to ordinary equity holders of the parent, adjusted to reflect the interest and the fair value on the convertible bonds. The weighted average number of ordinary shares used in the calculation of the diluted earnings per share is the weighted average number of ordinary shares in issue of the parent, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued on the conversion of all dilutive potential shares into ordinary shares.

The calculations of basic and diluted earnings per share are based on:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Earnings		
Profit attributable to ordinary equity holders of the parent used in the basic earnings per share calculation	**3,134,929**	2,725,525
Interest on convertible bonds	**272**	265
Profit attributable to ordinary equity holders of the parent used in the diluted earnings per share calculation	**3,135,201**	2,725,790

	Adjusted number of shares Six months ended 30 June	
	2025	2024
	(Unaudited)	(Unaudited)
Shares		
Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation	**5,937,754,754**	5,925,786,074
Effect of dilution – weighted average number of ordinary shares		
Restricted share units	**17,941,276**	20,143,737
Convertible bonds	**725,384**	703,086
Weighted average number of ordinary shares in issue during the period used in the diluted earnings per share calculation	**5,956,421,414**	5,946,632,897
Basic earnings per share (RMB per share)	**0.53**	0.46
Diluted earnings per share (RMB per share)	**0.53**	0.46

9. TRADE AND BILLS RECEIVABLES

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade receivables	**2,744,215**	3,139,904
Provision for impairment	**(10,056)**	(12,425)
Net carrying amount	**2,734,159**	3,127,479
Bills receivable	**59,575**	42,284
Total	**2,793,734**	3,169,763

An ageing analysis of trade receivables as at the end of the Reporting Period, based on the invoice date and net of loss allowance, is as follows:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 90 days	**2,731,434**	3,105,364
91 days to 180 days	**1,439**	5,447
Over 180 days	**1,286**	16,668
Total	**2,734,159**	3,127,479

An ageing analysis of bills receivable as at the end of the Reporting Period, based on the billing date, is as follows:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 90 days	**54,024**	41,441
91 days to 180 days	**5,551**	843
Total	**59,575**	42,284

The movements in the loss allowance for impairment of trade receivables are as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
At beginning of the period	**12,425**	30,604
Provision for impairment, net	**(2,369)**	6,943
At end of the period	**10,056**	37,547

10. CASH AND BANK BALANCES

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Cash and bank balances, unrestricted	**4,412,438**	2,101,651
Time deposits with original maturity of less than three months when acquired	**24,982**	221,050
Time deposits with original maturity of over three months when acquired *(note (a))*	**22,666,274**	20,298,865
Cash and bank balances	**27,103,694**	22,621,566

Note:

(a) The above investments represent time deposits with initial term of over three months when acquired (including three months) issued by commercial banks with annual return rates ranging from 1.3% to 5.5%. None of these investments are either past due or impaired. None of these deposits are pledged.

11. TRADE AND BILLS PAYABLES

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade payables	**268,654**	217,851
Total	**268,654**	217,851

An ageing analysis of the trade and bills payables as at the end of the Reporting Period, based on the invoice date and bills date, is as follows:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 90 days	**267,195**	211,421
91 days to 180 days	**957**	709
181 days to 1 year	**282**	2,055
Over 1 year	**220**	3,666
Total	**268,654**	217,851

12. OTHER PAYABLES AND ACCRUALS

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Accrued expenses	**1,391,192**	1,490,774
Staff payroll, welfare and bonus payables	**245,830**	438,431
Other tax payables	**111,297**	160,546
Payables for purchase of items of property, plant and equipment	**19,967**	27,481
Other payables	**447,164**	237,359
Total	**2,215,450**	2,354,591

13. SHARE CAPITAL

	30 June 2025	31 December 2024
	RMB	*RMB*
	(Unaudited)	(Audited)
Issued and paid: 5,947,150,070 shares of HK$0.00001 each (31 December 2024: 5,935,650,070 shares of HK$0.00001 each)	**52,393**	52,286

A summary of movements in the Company's share capital is as follows:

	Number of shares in issue	**Share capital** *RMB*
At 1 January 2025 (audited)	5,935,650,070	52,286
Issue of shares pursuant to the Group's Restricted Share Unit Scheme (the "**RSU Scheme**") adopted on 27 May 2019, HK$0.00001 each *(note (a))*	11,500,000	107
At 30 June 2025 (unaudited)	5,947,150,070	52,393

Note:

(a) On 22 April 2025, the Company issued 11,500,000 new ordinary shares to Computershare Hong Kong Trustees Limited (the "**RSU Trustee**") at the price of HK$2.9595 per share, pursuant to the terms of the RSU Scheme approved and adopted on 27 May 2019 for vesting of the restricted share units.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company's corporate governance practices are based on the principles and code provisions as set out in the Corporate Governance Code (the "**CG Code**") contained in Appendix C1 to the Listing Rules and the Company has adopted the CG Code as its own code of corporate governance.

The Board is of the view that the Company has complied with all the code provisions in effect as set out in Part 2 of the CG Code during the six months ended June 30, 2025, save for code provision C.2.1 of the CG Code.

CODE PROVISION C.2.1

Code provision C.2.1 of the CG Code states that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. The Company has appointed Ms. Zhong Huijuan ("**Ms. Zhong**") as both the chairlady and the chief executive officer of the Company. Due to the nature and the extent of the Group's operations and Ms. Zhong's in-depth knowledge and experience in the PRC pharmaceutical industry, the Board considers that the balance of power and authority under the present arrangement is not impaired and this structure will enable the Company to make and implement decisions promptly and effectively. The Board will continue to review and consider splitting the roles of chairlady of the Board and the chief executive officer of the Company at a time when it is appropriate by taking into account the circumstances of the Group as a whole.

The Board will periodically review and enhance its corporate governance practices to ensure that the Company continues to meet the requirements of the CG Code.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted its own code of conduct regarding securities transactions of the Company by Directors (the "**Company Code**") on terms no less exacting than the required standard set out in the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules. Specific enquiry has been made to all Directors by the Company and all Directors confirmed that they have complied with the Company Code during the six months ended June 30, 2025.

AUDIT COMMITTEE

The Board has established an audit committee (the "**Audit Committee**") with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph D.3 of Part 2 of the CG Code. The Audit Committee consists of three independent non-executive Directors, namely Mr. Chan Charles Sheung Wai (chairman of the Audit Committee), Mr. Lin Guoqiang and Ms. Yang Dongtao.

The Audit Committee and the external auditor, Ernst & Young, have reviewed the unaudited interim results of the Group for the six months ended June 30, 2025.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended June 30, 2025, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares) (as defined under the Listing Rules). As at June 30, 2025, no treasury shares (as defined under the Listing Rules) were held by the Company.

INTERIM DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS

The Board has declared the payment of an interim dividend of HK$23.16 cents per share for the six months ended June 30, 2025 (the interim dividend for the six months ended June 30, 2024: HK$20.10 cents per share). The interim dividend for 2025 will be paid to shareholders on Thursday, October 30, 2025 whose names appear on the register of members of the Company on Thursday, September 25, 2025. For the purpose of determining shareholders who are qualified for the interim dividend, the register of members of the Company will be closed from Wednesday, September 24, 2025 to Thursday, September 25, 2025, both days inclusive, during which period no transfer of shares will be effected. The record date for determining the entitlement of the shareholders to receive the interim dividend will be Thursday, September 25, 2025. In order to qualify for the interim dividend, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by 4:30 p.m. on Tuesday, September 23, 2025.

USE OF PROCEEDS FROM PREVIOUS FUNDRAISING ACTIVITIES AS AT JUNE 30, 2025

Use of proceeds from placing

On April 22, 2020, the Company entered into a placing agreement with Morgan Stanley & Co. International plc and Citigroup Global Markets Limited (the "**Placing Agents**"), pursuant to which the Placing Agents agreed to place 130,380,000 ordinary shares in the Company, or, failing which, to purchase themselves on a fully underwritten basis, to not fewer than six placees who are professional, institutional or other investors selected and procured by the Placing Agents and whose ultimate beneficial owners are independent third parties (the "**Placing**"). The Placing price was HK$26.75 per share.

The net proceeds from the Placing were approximately HK$3,477.20 million. As at December 31, 2024, the net proceeds had been fully utilized. Such proceeds were used for R&D projects, including but not limited to our domestic and overseas drug R&D, expanding our R&D team, and investment in technologies, in line with the purpose previously disclosed by the Company. For details of the use of proceeds, please refer to the section headed "Use of Proceeds from Placing" in the 2024 annual report of the Company.

Use of proceeds from issuance of convertible bonds

In January 2021, the Company successfully completed the issuance and listing of US$600 million zero-coupon convertible bonds due in 2026 to professional investors only. The net proceeds from the bonds were approximately US$595.65 million. In December 2022, the Company repurchased bonds with an aggregate principal amount of US$4 million. In January 2024, the Company redeemed the outstanding convertible bonds in the aggregate principal amount of US$590,622,000.

As at December 31, 2023, US$591.65 million was utilized and the net proceeds had been fully utilized. Such proceeds were primarily used for R&D expenditure (including but not limited to allocating funding to clinical trials for innovative drugs, innovative drugs development and/or in-license opportunities) as well as upgrading and expanding manufacturing facilities (including R&D facilities) and procuring equipment for its production facilities, in line with the purpose previously disclosed by the Company. For details of the use of proceeds, please refer to the section headed "Use of Proceeds from Issuance of Convertible Bonds" in the 2023 annual report and 2024 annual report of the Company.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the websites of The Stock Exchange of Hong Kong Limited (**www.hkexnews.hk**) and the Company (**www.hspharm.com**). The interim report for the six months ended June 30, 2025 will be available on the same websites in due course.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, August 18, 2025

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive Director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive Directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive Directors.

* *For identification purposes only*